Randomized, double-blind, parallel group, placebo controlled, tolerability, safety and pilot efficacy study of CPI-1189 in HIV infected individuals with cognitive and motor impairment
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2005
At a glance
- Drugs REN 1654 (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- 15 Oct 2005 New trial record.